Michelle Carr, Author at BioTuesdays

Developments

OKYO completes enrollment in Phase 2 dry eye clinical trial

OKYO Pharma (NASDAQ:OKYO) completed full enrollment of patients in the randomized portion of the Phase 2 clinical trial of topical ocular, OK-101, to treat dry eye disease (DED). A total of 240 patients were enrolled in...

September 8, 2023

Developments

Opus Genetics doses first patient with gene therapy in LCAS

Closely-held Opus Genetics dosed the first patient in its Phase 1/2, first-in-human clinical trial of OPGx-LCA5, an adeno-associated virus 8 vector designed to precisely deliver a functional LCA5 gene to the outer...

September 7, 2023

Developments

Cantor boosts biotech research with Josh Schimmer, Eric Schmidt

Cantor Fitzgerald bolstered its healthcare and biotech equity research team with the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D. “Having two of the most highly regarded analysts in the biotechnology...

September 6, 2023

Developments

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...

September 6, 2023

Executive Moves

Sernova names Cynthia Pussinen as CEO

Sernova (TSX:SVA; OTCQB:SEOVF; FSE/XETRA:PSH) appointed Cynthia Pussinen as CEO and a member of the board, succeeding Dr. Philip Toleikis, who will serve as chief technology officer. Ms. Pussinen’s expertise spans...

September 5, 2023

Developments

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...

September 5, 2023

Developments

Plus Therapeutics initiates Part B of ReSPECT-LM Phase 1/2a trial for LM

Plus Therapeutics (NASDAQ:PSTV) treated the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases (LM) from...

September 5, 2023

Developments

Ampio Pharmaceuticals unveils reverse stock split

The board of Ampio Pharmaceuticals (NYSEA:AMPE) approved a 20-to-1 reverse stock split of the company’s common stock, to be effective at close on Sept. 11. Ampio’s common stock is expected to begin trading on a...

August 31, 2023

Developments

NRx Pharmaceuticals submits IND for chronic pain

NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...

August 30, 2023

Developments

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

The FDA granted priority review designation for Zealand Pharma’s (NASDAQ:ZEAL; CVR-no. 20045078) dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients seven days of age and older with...

August 30, 2023

Author - Michelle Carr

OKYO completes enrollment in Phase 2 dry eye clinical trial

Opus Genetics doses first patient with gene therapy in LCAS

Cantor boosts biotech research with Josh Schimmer, Eric Schmidt

Palisade Bio in GI-licensing deal with Giliant Pharma

Sernova names Cynthia Pussinen as CEO

Tonix fails Phase 2 pain study; holds out hope in fatigue

Plus Therapeutics initiates Part B of ReSPECT-LM Phase 1/2a trial for LM

Ampio Pharmaceuticals unveils reverse stock split

NRx Pharmaceuticals submits IND for chronic pain

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

General

More